To recover your password please fill in your email address
Please fill in below form to create an account with us
Adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial (ANZUP1301).
See ANZCTR for full trial details >
|
Trial Summary: |
To determine the efficacy and safety of MMC in addition to BCG in patients with non-muscle, invasive bladder cancer. |
|
Supported By: |
Cancer Australia and National Health and Medical Research Council (NHMRC) |
|
Eligibility: |
Adults with resected, high-risk non-muscle, invasive bladder cancer (high grade Ta or any grade T1) suitable for intravesical chemotherapy treatment. |
|
Registration ID: |
ACTRN12613000513718 |
|
Participation: |
Australia |
|
Australian Lead Group: |
ANZUP |
|
Status: |
Recruiting |
|
Activation Date: |
02/12/2013 |
|
Chairs: |
Prof Dickon Hayne |
|
Contact: |